LC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Historically, cannabis was classified into two main species based on structural traits: Cannabis indica and Cannabis sativa. Cannabis indica is a relatively short plant with broad leaves, while Cannabis sativa is a taller plant with thinner leaves. However, modern taxonomic proposals suggests a single species, Cannabis sativa L., which is further divided into different strains according to their cannabinoid content. Due to the intensive selective breeding, many modern strains do not strictly align with their traditional indica or sativa lineage anymore. Cannabis plants vary widely in their cannabinoid profiles due to selective breeding. Hemp strains are bred for low THC content, often for fiber, while medical strains may prioritize high CBD, and recreational strains target high THC or specific balances. Quantitative analysis uses gas chromatography (GC), or GC combined with mass spectrometry (GC/MS), to measure cannabinoid content. Liquid chromatography (LC) can differentiate acid (e.g., THCA, CBDA) and neutral (e.g., THC, CBD) forms. Legal restrictions in many countries hinder consistent monitoring of cannabinoid profiles.
== History == In 1902 Victor Henri proposed a quantitative theory of enzyme kinetics, but at the time the experimental significance of the hydrogen ion concentration was not yet recognized. After Peter Lauritz Sørensen had defined the logarithmic pH-scale and introduced the concept of buffering in 1909, the German chemist Leonor Michaelis and Dr. Maud Leonora Menten (a postdoctoral researcher in Michaelis's lab at the time) repeated Henri's experiments and confirmed his equation, which is now generally referred to as Michaelis-Menten kinetics (sometimes also Henri-Michaelis-Menten kinetics). Their work was further developed by G. E. Briggs and J. B. S. Haldane, who derived kinetic equations that are still widely considered today a starting point in modeling enzymatic activity. The major contribution of the Henri-Michaelis-Menten approach was to think of enzyme reactions in two stages. In the first, the substrate binds reversibly to the enzyme, forming the enzyme-substrate complex. This is sometimes called the Michaelis complex. The enzyme then catalyzes the chemical step in the reaction and releases the product. The kinetics of many enzymes is adequately described by the simple Michaelis-Menten model, but all enzymes have internal motions that are not accounted for in the model and can have significant contributions to the overall reaction kinetics. This can be modeled by introducing several Michaelis-Menten pathways that are connected with fluctuating rates, which is a mathematical extension of the basic Michaelis Menten mechanism.
Mendeleev, reading de Boisbaudran's publication, sent a letter claiming that gallium was his predicted eka-aluminium. Although Lecoq de Boisbaudran was initially sceptical, and suspected that Mendeleev was trying to take credit for his discovery, he later admitted that Mendeleev was correct. In 1879, the Swedish chemist Lars Fredrik Nilson discovered a new element, which he named scandium: it turned out to be eka-boron. Eka-silicon was found in 1886 by German chemist Clemens Winkler, who named it germanium. The properties of gallium, scandium, and germanium matched what Mendeleev had predicted. In 1889, Mendeleev noted at the Faraday Lecture to the Royal Institution in London that he had not expected to live long enough "to mention their discovery to the Chemical Society of Great Britain as a confirmation of the exactitude and generality of the periodic law". Even the discovery of the noble gases at the close of the 19th century, which Mendeleev had not predicted, fitted neatly into his scheme as an eighth main group. Mendeleev nevertheless had some trouble fitting the known lanthanides into his scheme, as they did not exhibit the periodic change in valencies that the other elements did. After much investigation, the Czech chemist Bohuslav Brauner suggested in 1902 that the lanthanides could all be placed together in one group on the periodic table.
== Stigma == A 2016 report on stigma concluded "there is no country, society or culture where people with mental illness have the same societal value as people without mental illness". It is also important to comprehend that there are different types of stigmas: the most commonly understood is public stigma, which involves the negative or discriminatory attitudes that others may have about mental illness; it often leads to a more structural stigma, which involves policies of government and private organizations that intentionally or unintentionally limit opportunities for people with mental illness (examples include lower budgets for mental illness research or fewer mental health services in comparison to other types health care); finally, it is unavoidable to not talk about self-stigma, which refers to the negative attitudes, including internalized shame, that people with mental illness may have about their own condition. And stigma about mental illnesses seems to be widely endorsed as well as many misconceptions, the more common being: people with mental illness are homicidal maniacs who need to be feared; they have childlike perceptions of the world that should be marveled; or they are responsible for their illness because they have weak character. Indeed, the public seems to disapprove of people with psychiatric disabilities significantly more than people with related conditions such as physical illness. Severe mental illness has been likened to drug addiction, prostitution, and criminality.
Soon arose the notion of a tranquilizer which was quite different from any sedative or stimulant. The term tranquilizer took over the notions of sedatives and became the dominant term in the West through the 1980s. In Japan, during this time, the term tranquilizer produced the notion of a psyche-stabilizer and the term mood stabilizer vanished. Premarin (conjugated estrogens, introduced in 1942) and Prempro (a combination estrogen-progestin pill, introduced in 1995) dominated hormone replacement therapy (HRT) regimens during the 1990s. Though not designed to cure any disease, HRT is prescribed to improve quality of life and as a preventative measure, such as treating post-menopausal symptoms. In the 1960s and early 1970s, more physicians began to prescribe estrogen for their female patients. Between 1991 and 1999, Premarin was listed as the most popular prescription and best-selling drug in America. The first oral contraceptive, Enovid, was approved by FDA in 1960. Oral contraceptives inhibit ovulation and so prevent conception. Enovid was known to be much more effective than alternatives including the condom and the diaphragm. As early as 1960, oral contraceptives were available in several different strengths by every manufacturer. In the 1980s and 1990s, an increasing number of options arose including, most recently, a new delivery system for the oral contraceptive via a transdermal patch. In 1982, a new version of "the pill" was introduced, known as the biphasic pill. By 1985, a new triphasic pill was approved.
Sources: en.wikipedia.org
=== Via biodegradation of trifluomethyl compounds === Trifluoroacetic acid is not produced biologically, but it is a breakdown product of various organofluorine compounds, e.g., the volatile anesthetic agent halothane. It also may be formed by hydroxyl radical-initiated atmospheric oxidation of the commonly used refrigerant 1,1,1,2-tetrafluoroethane (R-134a). Moreover, it is formed as an atmospheric degradation product of almost all fourth-generation synthetic refrigerants, also called hydrofluoroolefins (HFO), such as 2,3,3,3-tetrafluoropropene. Trifluoroacetic acid is also formed by the degradation of some pesticides that contain a trifluoromethyl group (-CF3), such as flufenacet. The German Environment Agency estimated that pesticide use releases approximately 500 metric tonnes of TFA annually in Germany alone, while refrigerants account for around 1170 metric tonnes per year.
=== Size === The smallest bat, and one of the smallest mammals, is Kitti's hog-nosed bat (Craseonycteris thonglongyai), which is 29–33 mm (1+1⁄8–1+1⁄4 in) long with a 150-millimetre (6 in) forearm and weighs 2 oz (56+11⁄16 g). The largest species is the giant golden-crowned flying fox (Acerodon jubatus), which can weigh 1.5 kg (3+1⁄4 lb) with a wingspan of 1.6 m (5 ft 3 in). Larger bats tend to use lower frequencies and smaller bats higher for echolocation; high-frequency echolocation is better at detecting smaller prey. Small prey may be absent in the diets of large bats as they are unable to detect them.
Societal views, influenced by tradition, a lack of knowledge on anatomy, or sexism, can significantly impact a person's decision to alter their own or another person's genitalia. Women may want to alter their genitalia (vagina or vulva) because they believe that its appearance, such as the length of the labia minora covering the vaginal opening, is not normal, or because they desire a smaller vaginal opening or tighter vagina. Women may want to remain youthful in appearance and sexual function. These views are often influenced by the media, including pornography, and women can have low self-esteem as a result. They may be embarrassed to be naked in front of a sexual partner and may insist on having sex with the lights off. When modification surgery is performed purely for cosmetic reasons, it is often viewed poorly, and some doctors have compared such surgeries to female genital mutilation (FGM). Female genital mutilation, also known as female circumcision or female genital cutting, is genital modification with no health benefits. The most severe form is Type III FGM, which is infibulation and involves removing all or part of the labia and the vagina being closed up. A small hole is left for the passage of urine and menstrual blood, and the vagina is opened up for sexual intercourse and childbirth.
China is a leading producer of indium (290 tonnes in 2016), followed by South Korea (195 t), Japan (70 t) and Canada (65 t). The Teck Resources refinery in Trail, British Columbia, is a large single-source indium producer, with an output of 32.5 tonnes in 2005, 41.8 tonnes in 2004 and 36.1 tonnes in 2003. The primary consumption of indium worldwide is LCD production. Demand rose rapidly from the late 1990s to 2010 with the popularity of LCD computer monitors and television sets, which now account for 50% of indium consumption. Increased manufacturing efficiency and recycling (especially in Japan) maintain a balance between demand and supply. According to the UNEP, indium's end-of-life recycling rate is less than 1%.
=== Additional doses === Immunity following a course of doses is typically long lasting, and additional doses are usually not needed unless the person has a high risk of contracting the virus. Those at risk may have tests done to measure the amount of rabies antibodies in the blood, and then get rabies boosters as needed. Following administration of a booster dose, one 2002 study found 97% of immunocompetent individuals demonstrated protective levels of neutralizing antibodies after ten years. A 2021 study found that in patients who had received PrEP rabies vaccines in the form of 2 doses or 3-doses 10-24 years ago, rabies immunological memory was reactivated in all patients within 7 days after a single intramuscular booster immunization. The WHO recommends that patients who had received at least 2 doses of PrEP in the past be given after exposure either of the following three approved protocols of rabies vaccine booster administration: 1-site ID on days 0 and 3; or 4-sites ID on day 0; or 1-site IM on days 0 and 3. RIG should not be given to patients who had undergone PrEP.
Sources: en.wikipedia.org
Its transport and industrial capabilities were limited, which Liu attempted to remedy through major works. Throughout Liu's rule, new roads were constructed connecting the Kham and Yashu (Ya'an) areas to Sichuan and from Ningshu to Yunnan: however, none were made linking Kham and Ningshu. An airstrip was also built at Kangding. Certain large-scale projects such as the hydroelectric plant built in 1944 were made possible due to the central government's wartime mobilization and Liu Wenhui's stated stance to build up Xikang into a rear base to resist the Japanese from, which resulted in him gaining more subsidies from Chiang. Liu also focused on healthcare, completing the Xikang Provincial Hospital in December 1941 and establishing health centers in Batang and Garzê in October 1941. Liu's government also continued attempts to settle the frontier, proposing in 1938 to resettle 40,000 war refugees in Ningshu and noting that there was enough arable land in the region for 80,000 people. For Lawson, this was consistent with Liu's "long-standing colonial engagement with Kham" that he believed to be in China's national interest.
Although trials are commonly conducted at major medical centers, some participants are excluded due to the distance and expenses required for travel, leading to hardship, disadvantage, and inequity for participants, especially those in rural and underserved communities. "Decentralized clinical trials" minimize or eliminates the need for patients to travel to sites, and are now more widespread; a capability improved by telehealth and wearable technologies.
=== Peptide synthesis/ACTH === The first chemical synthesis of an active peptide hormone, the nine amino acid cyclic peptide, oxytocin, was achieved in 1954 by du Vigneaud for which he was awarded the Nobel Prize. At the same time, the isolation and structure determination of the anterior pituitary hormone, ACTH, was being pursued in three laboratories. The peptide was eventually determined to be 39 amino acids in length, however enzymatic and mild acid cleavage suggested that a structure comprising only the first 24 amino acids had full biological activity. It was apparent from the outset that ACTH contained the amino acid Arginine and thus methods had to be developed for the incorporation of this basic amino acid into peptides. Hofmann and his group set about this task. Their efforts led to the synthesis of the melanocyte stimulating hormone, β-MSH, which corresponds to the first 13 amino acids of ACTH and to the synthesis of a fully active ACTH peptide corresponding to the amino acid sequence of the first 23 amino acids. In the course of the peptide synthetic work on ACTH, a novel chain cleavage was observed at an acyl-proline linkage while removing protecting groups using metallic sodium in liquid ammonia. This unexpected reaction has subsequently proved useful in special analytical cases.
=== Injury === If the vitreous pulls away from the retina, it is known as a vitreous detachment. As the human body ages, the vitreous often liquefies and may collapse. This is more likely to occur, and occurs much earlier, in eyes that are nearsighted (myopia). It can also occur after injuries to the eye or inflammation in the eye (uveitis). The collagen fibres of the vitreous are held apart by electrical charges. With aging, these charges tend to reduce, and the fibres may clump together. Similarly, the gel may liquefy, a condition known as synaeresis, allowing cells and other organic clusters to float freely within the vitreous humour. These allow floaters which are perceived in the visual field as spots or fibrous strands. Floaters are generally harmless, but the sudden onset of recurring floaters may signify a posterior vitreous detachment or other diseases of the eye. Posterior vitreous detachment: Once liquid vitreous enters the sub-hyaloid space between the vitreous cortex and the retina, it may strip the vitreous cortex off the retina with each eye movement (see Saccade).
== Diagnosis == The disease may be diagnosed based on a clinical examination, which identifies signs and symptoms generally associated with the people who have the condition. Genetic testing for known pathological variants is preferred, by testing of the COL6A1, COL6A2, COL6A3 and COL12A1 genes. In the case of a VUS, testing of dermal fibroblast culture is used for an accurate diagnosis. Additional laboratory tests may be performed before genetic testing, such as creatine kinase (CK) blood test, MRI of the muscles, and electromyography (EMG). Phenotypes of overlap between Ullrich congenital muscular dystrophy (UCMD) and Bethlem can be assumed. In the differential diagnosis of UCMD, even in patients without finger contractures, Bethlem myopathy could be considered.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.